Investment companies Vivo Capital and Advantech Capital completed a $15m investment in Sinovac Research and Development, a unit of Sinovac Biotech, a provider of biopharmaceutical products in China. "Our proven track record of successful vaccination development has allowed us to make excellent progress on CoronaVac, our Covid-19 vaccine candidate, and the funding from Advantech Capital and Vivo Capital will provide us with the necessary resources to continue our work at this unprecedented pace. We are proud to be on the frontlines fighting the Covid-19 pandemic and appreciate the support of Advantech Capital and Vivo Capital as well as cooperation from all levels of the Chinese Government, who have been essential in allowing us to move forward at full speed with the development of CoronaVac without compromising our high safety standards and procedures," Weidong Yin, Chairman, Sinovac President and CEO.